Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival-Reference-Cited by-同舟云学术

Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival

Published:2012-10 Issue:5 Volume:12 Page:313-321
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Gradishar William J.,Krasnojon Dimitry,Cheporov Sergey,Makhson Anatoly N.,Manikhas Georgiy M.,Clawson Alicia,Bhar Paul,McGuire John R.,Iglesias Jose

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Cancer Statistics 2012;Siegel;A Cancer Journal for Clinicians,2012

3. Chemotherapy for metastatic breast cancer;Mayer;Hematol/Oncol Clin North Am,2007

4. Taxanes in breast cancer: an update;Conlin;Curr Oncol Rep,2007

5. Taxanes in the first-line chemotherapy of metastatic breast cancer: review;Friedrich;Eur J Gynaecol Oncol,2004

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of nanoparticle albumin‐bound paclitaxel in taxane‐pretreated metastatic breast cancer patients;Cancer;2024-01-25

2. Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study;The Oncologist;2023-10-26

3. Efficacy and safety of pyrotinib in combination with albumin‑bound paclitaxel for the treatment of HER2‑positive advanced breast cancer: A real‑world study;Oncology Letters;2023-06-06

4. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial;Annals of Oncology;2023-06

5. Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system;Indian Journal of Pharmacology;2023